Taken together, there is a clear potential for the use of rilpivirine to interfere with the JAK-STAT pathway and, while the evidence was with liver fibrosis, there could be similar effects on hepatocarcinoma, warranting further investigation. Here, SOAT1 is linked to Hepatic fibrosis.